{"id":"xenical-pegasys-copegus","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"10-15","effect":"Hemolytic anemia"},{"rate":"5-10","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Depression/psychiatric effects"},{"rate":"20-30","effect":"Gastrointestinal disturbance (orlistat)"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL175247","moleculeType":"Small molecule","molecularWeight":"495.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Xenical (orlistat) is a lipase inhibitor for weight management, while Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) together form a standard hepatitis C treatment regimen. Pegasys is a long-acting interferon that activates innate immunity against HCV, and Copegus is a nucleoside analog that inhibits viral RNA polymerase, working synergistically to suppress hepatitis C virus replication.","oneSentence":"This is a combination antiviral therapy for hepatitis C that uses a nucleoside analog and an interferon to inhibit viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:15.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C infection (genotype 1-6)"},{"name":"Obesity/weight management (orlistat component)"}]},"trialDetails":[{"nctId":"NCT00207311","phase":"PHASE4","title":"Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2005-08","conditions":"Fatty Liver, Hepatitis C","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xenical (orlistat)","Pegasys (PEG-Interferon alpha-2a)"],"phase":"marketed","status":"active","brandName":"Xenical, Pegasys, Copegus","genericName":"Xenical, Pegasys, Copegus","companyName":"Brooke Army Medical Center","companyId":"brooke-army-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antiviral therapy for hepatitis C that uses a nucleoside analog and an interferon to inhibit viral replication. Used for Chronic hepatitis C infection (genotype 1-6), Obesity/weight management (orlistat component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}